Sep 2nd, 2021 - The clinical laboratory continues to play a critical role in managing the coronavirus pandemic. Numerous US Food and Drug Administration emergency use authorization (EUA) and laboratory-developed test (LDT) serologic assays have become available. The performance characteristics of these assays and their clinical utility continue to be defined in real time during this pandemic. The AACC convened...

Feb 6th, 2018 - Purpose In response to advances in the field, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) recently updated their recommendations for molecular testing for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors. ASCO has a policy and set...

Jun 18th, 2016 - Enhanced half-life factor VIII and IX products are being introduced into routine clinical practice. Published data report on clinical trials and there are limited data available on how to use these products in routine clinical practice. Many patients, for example, those with a past history of an inhibitor, have been excluded from clinical trials and there are limited data published on children....

Mar 2nd, 2016 - L-asparaginase is an integral component of therapy for acute lymphoblastic leukemia. However, asparaginase-related complications, including the development of hypersensitivity reactions, can limit its use in individual patients. Of considerable concern in the setting of clinical allergy is the development of neutralizing antibodies and associated asparaginase inactivity. Also problematic in the...

Apr 9th, 2013 - To establish evidence-based recommendations for the molecular analysis of lung cancers that are required to guide EGFR- and ALK-directed therapies, addressing which patients and samples should be tested, and when and how testing should be performed. Three cochairs without conflicts of interest were selected, one from each of the 3 sponsoring professional societies: College of American Pathologi...

Nov 20th, 2012 - Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.|2012|Collins PW,Chalmers E,Hart DP,Liesner R,Rangarajan S,|therapeutic use,prevention & control,antagonists & inhibitors,genetics,immunology,therapeutic use,antagonists & inhibitors,genetics,immunology,therapeutic use,therapeutic use,genetics,immunology,...

Sep 3rd, 2011 - Towards a recommendation for the standardization of the measurement of platelet-dependent thrombin generation.|2011| ,|metabolism,methods,standards,methods,standards,biosynthesis,

Jan 22nd, 2011 - In April 2010, a working group sponsored by the National Heart, Lung, and Blood Institute was assembled to identify research strategies to improve our understanding of alloimmunization caused by the transfusion of allogeneic blood components and to evaluate potential approaches to both reduce its occurrence and manage its effects. Significant sequelae of alloimmunization were discussed and iden...

Jul 16th, 2010 - Like many other complex human disorders of unknown aetiology, autoimmune-mediated type 1 diabetes may ultimately be controlled via a therapeutic approach that combines multiple agents, each with differing modes of action. The numerous advantages of such a strategy include the ability to minimize toxicities and realize synergies to enhance and prolong efficacy. The recognition that combinations ...

May 25th, 2010 - Medullary carcinoma.|2010|Tuttle RM,Ball DW,Byrd D,Daniels GH,Dilawari RA,|biosynthesis,blood,diagnosis,epidemiology,radiotherapy,surgery,diagnosis,epidemiology,radiotherapy,surgery,epidemiology,

Apr 22nd, 2008 - Evidence-based guidelines are presented on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. They include details of therapeutic products available in the UK and they update and replace previous United Kingdom Haemophilia Centre Doctors' Organisation guidelines.